The purpose of this study is to determine the short-term effects of the antimalarial medication, hydroxychloroquine (HCQ), compared with placebo using frequently sampled intravenous glucose tolerance testing (FSIGTT) methodology to study changes in insulin secretion and glucose tolerance in subjects at risk for developing Type 2 diabetes.
Diabetes is approaching epidemic proportions in the United States. This study evaluates the mechanisms of action of a generic drug that may have effects on glucose metabolism.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
32
Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
Thirteen weeks of oral placebo provided as capsules
University of Pittsburgh, Montefiore Hospital
Pittsburgh, Pennsylvania, United States
Insulin Sensitivity
Change from baseline in the insulin sensitivity index (Si)
Time frame: 13 weeks after baseline measurement
Beta Cell Function
Change from baseline in the disposition index (DI)
Time frame: 13 weeks after baseline measurement
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.